Trials / Recruiting
RecruitingNCT07047690
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nemolizumab | Subcutaneous Injection |
| DRUG | Placebo | Subcutaneous Injection |
Timeline
- Start date
- 2026-02-20
- Primary completion
- 2028-05-28
- Completion
- 2028-07-23
- First posted
- 2025-07-02
- Last updated
- 2026-03-31
Locations
3 sites across 2 countries: United States, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07047690. Inclusion in this directory is not an endorsement.